COMPOSITIONS AND METHODS OF TOLERIZING A PRIMATE TO AN ANTIGEN

(19)

(11)

EP 1 587 541 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	24.10.2012 Bulletin 2012/43

(45)	Mention of the grant of the patent:
	12.09.2012 Bulletin 2012/37

(21)	Application number: 04706089.2

(22)	Date of filing: 28.01.2004

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
C07K 16/28^(2006.01)
A61P 37/06^(2006.01)
A61P 43/00^(2006.01)
G01N 33/50^(2006.01)

A61K 45/06^(2006.01)
C07K 16/46^(2006.01)
C12N 15/13^(2006.01)
C12Q 1/02^(2006.01)

(86)	International application number:
	PCT/US2004/002643

(87)	International publication number:
	WO 2004/067554 (12.08.2004 Gazette 2004/33)

(54)	COMPOSITIONS AND METHODS OF TOLERIZING A PRIMATE TO AN ANTIGEN ZUSAMMENSETZUNGEN UND VERFAHREN ZUR INDUZIERUNG VON TOLERANZ GEGEN EIN ANTIGEN IN EINEM PRIMATEN COMPOSITIONS ET PROCEDES D'INDUCTION DE TOLERANCE D'UN PRIMATE A UN ANTIGENE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
	Designated Extension States:
	AL LT LV MK

(30)

Priority:

29.01.2003 US 353708

(43)	Date of publication of application:
	26.10.2005 Bulletin 2005/43

(73)	Proprietors:
	ISIS Innovation Limited Summertown, Oxford OX2 7SG (GB) Cambridge Enterprise Limited Trinity Lane Cambridge Cambridgeshire CB2 1TN (GB)

(72)	Inventors:
	FREWIN, Mark Oxford OX4 2JJ (GB) WALDMANN, Herman Oxford OX2 7QY (GB) GORMAN, Scott Witney, Oxon OX8 8HL (GB) HALE, Geoff Marston Oxford OX3 OSJ (GB) RAO, Patricia Acton, MA 01720 (US) KORNAGA, Tadeusz Cambridge, MA 02139 (US) RINGLER, Douglas Boston, MA 02116 (US) COBBOLD, Stephen Witney Oxfordshire OX8 8PS (GB) WINSOR-HINES, Dawn Framingham, MA 01701 (US)

(74)	Representative: Walcher, Armin et al
	Louis, Pöhlau, Lohrentz & Segeth Postfach 3055 90014 Nürnberg 90014 Nürnberg (DE)

(56)

References cited: :

WO-A-90/15152

WO-A2-02/102853

KOULMANDA M ET AL: "The effect of mycophenolate mofetil (MM) with and without anti-CD4 MAb (GK1.5) on fetal islet iso-, allo, and xenografts in NOD/Lt female mice" CELL TRANSPLANTATION, vol. 5, no. 5 SUPPL. 2, 1996, page 59, XP002438980 & THIRD INTERNATIONAL CONGRESS OF THE CELL TRANSPLANT SOCIETY; MIAMI BEACH, FLORIDA, USA; SEPTEMBER 29-OCTOBER 2, 1996 ISSN: 0963-6897
LU X ET AL: "Prolongation of islet xenograft survival with combined treatment of 15-deoxyspergualin or cyclosporine and anti-CD4 monoclonal antibody." TRANSPLANTATION PROCEEDINGS FEB 1995, vol. 27, no. 1, February 1995 (1995-02), pages 298-299, XP008080491 ISSN: 0041-1345
AKITA K ET AL: "EFFECT OF KF506 AND ANTI-CD4 THERAPY ON FETAL PIG PANCREAS XENOGRAFTS AND HOST LYMPHOID CELLS IN NOD/LT, CBA, AND BALB/C MICE" CELL TRANSPLANTATION, ELSEVIER SCIENCE, US, vol. 3, no. 1, 1994, pages 61-73, XP000575177 ISSN: 0963-6897
ANONYMOUS: 'CellCept Mycophenolate mofetil', [Online] Roche Retrieved from the Internet: <URL:http://www.cellcept.de>


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).